Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston

Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare
                             Conference in Boston

PR Newswire

SAN FRANCISCO, March 1, 2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ --Nektar Therapeutics' (Nasdaq:
NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve, is
scheduled to present at the 33rd Annual Cowen and Company Healthcare
Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at
8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the
Investor Relations, Events Calendar section of the Nektar website This webcast will be available for replay until April
8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and advanced polymer conjugation
technology platforms. Nektar has a robust R&D pipeline of potentially
high-value therapeutics in pain, oncology and other therapeutic areas. In the
area of pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which
has completed Phase 3 clinical development as a once- daily, oral tablet for
the treatment of opioid-induced constipation. This agreement also includes
NKTR-119, an earlier stage development program that is a co-formulation of
naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel
mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2
development in osteoarthritis patients with chronic knee pain. NKTR-192, a
novel mu-opioid analgesic in development to treat acute pain is in Phase 1
clinical development. In oncology, etirinotecan pegol (NKTR-102) is being
evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of
metastatic breast cancer and is also in Phase 2 studies for the treatment of
ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe
through partnerships with leading biopharmaceutical companies, including UCB's
Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for
hepatitis C and Amgen's Neulasta® for neutropenia. Additional
development-stage products that leverage Nektar's proprietary technology
platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program,
which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama and Hyderabad, India. Further information
about the company and its drug development programs and capabilities may be
found online at

Jennifer Ruddock

SOURCE Nektar Therapeutics

Press spacebar to pause and continue. Press esc to stop.